Document is current
Any future updates will be listed below
-
Authors
Graziani, Francesca https://orcid.org/0000-0002-4520-5689
Biagini, Elena https://orcid.org/0000-0003-0295-0440
Argirò, Alessia https://orcid.org/0000-0002-6394-9948
Citro, Rodolfo https://orcid.org/0000-0002-7796-6298
Iaccarino, Guido https://orcid.org/0000-0002-8997-835X
Lanzillo, Chiara https://orcid.org/0000-0001-5469-6283
Monte, Ines https://orcid.org/0000-0001-7059-7525
Pieruzzi, Federico https://orcid.org/0000-0002-1302-6846
Zuchi, Cinzia https://orcid.org/0000-0003-3955-3879
Pieroni, Maurizio https://orcid.org/0000-0002-6830-4292
- License Information
-
More Information
Article History
Received: 5 December 2025
Accepted: 25 June 2026
First Online: 9 July 2026
Declarations
:
: Not applicable.
: Not applicable.
: FG: participated in advisory board for Takeda, Amicus, Sanofi, Chiesi; received speaker fees from Takeda, Amicus, Sanofi, received grant from Takeda. EB: participated in advisory boards, received lecture fees from Sanofi-Genzyme, Chiesi, Amicus, Takeda and BMS. RC: has no conflict of interest to declare. GI: participated in advisory boards for Amicus Therapeutics, Sanofi and Chiesi Therapeutics. CL: participated in advisory board for Sanofi; received speaker fees from Takeda, Amicus, Sanofi. IM: participated in advisory boards for Amicus and Sanofi Therapeutics. FP: participated in an advisory board for Sanofi. AA has no conflicts of interest to declare. CZ participated in an advisory board for Sanofi. MP: participated in an advisory board for Sanofi and received advisory board and lecture fees from Sanofi-Genzyme, Chiesi, Amicus, Takeda and BMS.
